Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
Description
Open-label study of SF-2577 plus pembrolizumab in advanced, recurrent small cell ovarian cancer as well as select additional ovarian and endometrial cancers within the SWI/SNF pathway.